RxDoctor Payments Data

Suma Magge, MD

Gastroenterology · Stamford, CTNPI 1619134392

Payments from drug & device makers

$2,025in general payments, 2019–2025

Across 39 payments — averaging $51.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$757
  • Takeda Pharmaceuticals U.S.A., Inc.$329
  • AbbVie$275
  • Medtronic$188
  • Novo Nordisk$147
  • Sanofi$141
  • plus $188 from 4 others

What the payments were for

  • Food & beverage$1,97497%
  • Education$513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,025 in reported general payments places this provider in the 40th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$111,348
Medicare patients
509
Services billed
864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$410,634
Humira(Cf) PenAdalimumab26$169,800
XeljanzTofacitinib Citrate13$73,984
Mesalamine25$18,850
LinzessLinaclotide30$16,842
TrulancePlecanatide21$11,454
Alosetron Hcl12$9,885
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates80$4,915
Dexlansoprazole DrDexlansoprazole17$4,703
Omeprazole306$4,253
Lubiprostone26$3,362
Famotidine62$3,362
Pantoprazole Sodium142$2,022
Esomeprazole Magnesium29$667
Amitriptyline Hcl48$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$757$410,63415 claims
AbbVieLinzess$275$16,84230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →